Skip to main content
Premium Trial:

Request an Annual Quote

Enzon, Micromet End Antibody Drug R&D Partnership

NEW YORK, Nov. 28 (GenomeWeb News) - Enzon Pharmaceuticals and Micromet will end their collaboration to identify and develop antibody-based therapeutics for inflammatory and autoimmune diseases, the companies said today.


The decision was made after Enzon decided to redirect its efforts onto new business objectives, including a greater focus on cancer, the companies said. Enzon and Micromet had been collaborating since April 2002.


The companies said that the termination of their collaboration does not affect their other agreements, including a cross-license agreement between the parties and a marketing agreement under which Micromet is the exclusive marketer of the companies' combined intellectual property estate in the field of single-chain antibody technology.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.